💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tenofovir Disoproxil

CHEMBL1538 Phase 4 Approuvé Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
519.4 g/mol
LogP
1.6
Phase
4

Tenofovir disoproxil is a prodrug form of tenofovir that is hydrolyzed in plasma to tenofovir, which is then phosphorylated intracellularly to tenofovir diphosphate, an NRTI that inhibits HIV-1 and HBV reverse transcriptase. It was the first once-daily NRTI approved and transformed HIV treatment by enabling simplified regimens. While effective, its higher plasma tenofovir exposure compared to the alafenamide prodrug is associated with greater renal tubular toxicity and bone mineral density loss with long-term use.

Masse moléculaire

519,4000 g/mol

LogP

1,60

TPSA

185,00 Ų

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Infectious Disease Rheumatoid Arthritis Osteoporosis Generalized Anxiety Disorder Insomnia Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Hyperlipidemia Obesity Lymphoma Hypertension Gout HIV/AIDS Hepatitis C Tuberculosis Heart Failure Cardiovascular Disease

Mécanisme d'action

Provides an essential mineral element required for numerous enzymatic reactions, structural proteins, and physiological processes. Supplementation addresses deficiency states.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Provides an essential mineral element required for numerous enzymatic reactions, structural proteins, and physiological processes. Supplementation addresses deficiency states.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C

                

                

                
                

                    
InChI

                    
InChI=1S/C19H30N5O10P/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22)/t14-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H30N5O10P

                    

                    
                    

                        
HBD / HBA

                        
1 / 14

                    

                    
                    

                        
Liaisons Rotatives

                        
17

                    

                    
                    
                    

                        
Atomes Lourds

                        
35

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
Tenofovir disoproxil is a prodrug form of tenofovir that is hydrolyzed in plasma to tenofovir, which is then phosphorylated intracellularly to tenofovir diphosphate, an NRTI that inhibits HIV-1 and HBV reverse transcriptase. It was the first once-daily NRTI approved and transformed HIV treatment by enabling simplified regimens. While effective, its higher plasma tenofovir exposure compared to the alafenamide prodrug is associated with greater renal tubular toxicity and bone mineral density loss with long-term use.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Provides an essential mineral element required for numerous enzymatic reactions, structural proteins, and physiological processes. Supplementation addresses deficiency states.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Tenofovir Disoproxil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1538.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5481350.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.